Viral protein R (Vpr), one of the accessory gene products encoded by the human immunodeficiency virus type 1 (HIV-1) genome, has a number of functions, including causing a growth arrest of HIV-1-infected cells and possibly the death of uninfected bystander cells. In microbial assay systems, the C-terminal portion of Vpr can cause cell death when added externally, and when expressed in yeast it causes growth arrest. In this study we have sought to obtain inhibitors of the Vpr functions that affect the microbial systems. Our first approach employed peptide display, which identified a number of sequences, including a heptapeptide sequence, GETRAPL, involved in binding to the C-terminus of Vpr. To determine whether GETRAPL could block the extracellular cytocidal activity of Vpr, the heptapeptide was synthesized and found to have some blocking activity in microbial assays. A second approach led to the finding that melittin inhibitors had activity against Vpr extracellular activities. In a third approach, compounds were tested against the Vpr-induced growth arrest. A number of compounds were found to abrogate the growth arrest, and some also inhibited Vpr's extracellular activity.
References
1.
Miller, R.H., Sarver, N. (1997). HIV accessory proteins as therapeutic targets. Nature Med.3:389.
2.
Emerman, M. (1996). HIV-1, Vpr and cell cycle. Curr. Biol.6:1096.
3.
Goh, W.C., Rogel, M.E., Kinsey, C.M., Michael, S.F., Fultz, P.N., Nowak, M.A., Hahn, B.H., Emerman, M. (1998). HIV-1 Vpr increases viral expression by manipulation of the cell cycle—a mechanism for selection of Vpr in vivo. Nature Med.4:65.
4.
Arunagiri, C.K., Macreadie, I.G., Hewish, D.R., Azad, A.A. (1997). A membrane-active C-terminal domain of HIV-1 accessory protein Vpr penetrates human cells and causes mitochondrial dysfunction and apoptosis. Apoptosis. 2:69.
5.
Macreadie, I.G., Arunagiri, C.K., Hewish, D.R., White, J.F., Azad, A.A. (1996). Extracellular addition of a domain of HIV-1 Vpr containing the amino acid sequence motif H(S/F)RIG causes cell membrane permeabilization and death. Mol. Microbiol.19:1185.
6.
Macreadie, I.G., Kirkpatrick, A., Strike, P.M., Azad, A.A. (1997). Cytocidal activities of HIV-1 Vpr and Saclp peptides bioassayed in yeast. Protein Pept. Lett.4:173.
7.
Finkel, T.H., Tudor-Williams, G., Bandra, N.K., Cotton, M.F., Curiel, T., Monks, C., Baba, T.W., Ruprecht, R.M., Kupfer, A. (1995). Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nature Med.1:129.
8.
Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M., Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:123.
Heinzinger, N.K., Bukrinsky, M.I., Haggerty, S.A., Ragland, A.M., Kewalramani, V., Lee, M-A., Gendelman, H.E., Ratner, L., Stevenson, M., Emerman, M. (1994). The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc. Natl. Acad. Sci. USA.91:7311.
11.
Macreadie, I.G., Castelli, L.A., Hewish, D.R., Kirkpatrick, A., Ward, A.C., Azad, A.A. (1995). A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects. Proc. Natl. Acad. Sci. U S A.92:2770.
12.
Macreadie, I.G., Thorbum, D.R., Kirby, D.M., Castelli, L.A., de Rozario, N.L., Azad, A.A. (1997). HIV-1 protein Vpr causes gross mitochondrial dysfunction in the yeast Saccharomyces cerevisiae. FEBS Lett.410:145.
13.
Failla, P., Castelli, L.A., Azad, A.A., Macreadie, I.G. (1997). Bactericidal properties of HIV-1 Vpr C-terminal sequences. Protein Pept. Lett.4:383.
Smith, G.P., Scott, J.K. (1993). Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol.217:228.
16.
Adachi, A., Gendelman, H.E., Koenig, S., Folks, T., Willey, R., Rabson, A., Martin, M.A. (1986). Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious clone. J. Virol.59:284.
17.
Blondelle, S.E., Houghton, R.A., Pfrez-Payd, E. (1996). Identification of inhibitors of melittin using nonsupport-bound combinatorial libraries. J. Biol. Chem.271:4093.
18.
Hewish, D., Werkmeister, J., Kirkpatrick, A., Curtain, C., Pantela, G., Rivett, D.E. (1996). Peptide inhibitors of melittin action. J. Protein Chem.15:395.
19.
Rivett, D.E., Kirkpatrick, A., Macreadie, I.G., McKenzie, J.A., Raison, R.L., Weston, C.A., Ward, A.C. (1990). Nittilem, the reverse sequence peptide of melittin retains biological activity. J. Protein Chem.9:350.
20.
Yao, S.Y., Azad, A.A., Macreadie, I.G., Norton, R.S. (1998). Helical structure of polypeptides from the C-terminal half of HIV-1 Vpr. Protein Pept. Lett.5:127.
21.
Yao, S., Torres, A.M., Azad, A.A., Macreadie, I.G., Norton, R.S. (1998). Solution structure of peptides from HIV-1 Vpr protein that cause membrane permeabilisation and growth arrest. J. Pept. Sci.4:426.
